The Benchmark Company

Upgrades or downgrades from analysts can cause a stock to rally or plummet. Traders may wish to stay alert of ratings changes as they could serve as the basis for building a winning trade strategy. On Tuesday, Benzinga Professional covered 12 stocks receiving new bullish or bearish ratings from...

Listed below are today's Top Upgrades covered by Benzinga: Jefferies & Company Upgrades Riverbed Technology (NASDAQ: RVBD) to Hold: Jefferies notes, "We still believe the WAN Optimization market is maturing – an ongoing structural negative for the business. Nonetheless, the shares have traded...

According to a research report published this morning, Benchmark maintains its price target of $20 for ValueClick (NASDAQ: VCLK) and upgrades its rating from Hold to Buy. Benchmark mentions in the report, “ValueClick is a resilient company that is highly adaptive. Evidence includes the solid cash...

Two stocks were the recipients of new bearish signals and fifteen others received bullish ratings from analysts on Tuesday. New bearish ratings are initiations with or downgrades to a Sell, Underperform or Underweight rating. New bullish ratings are initiations with or upgrades to Buy, Overweight...

Listed below are today's Top Initiations covered by Benzinga: Benchmark Initiates Move (NASDAQ: MOVE) at Buy: Benchmark notes, “Move is a small-cap digital advertising company in the later stages of a turnaround. We believe 2012 will mark a return to revenue growth, as new product initiatives...

Benchmark initiates coverage on Move (NASDAQ: MOVE) with a Buy rating and a price target of $11. Benchmark notes, “Move is a small-cap digital advertising company in the later stages of a turnaround. We believe 2012 will mark a return to revenue growth, as new product initiatives increase...

Benchmark initiates a Buy rating on Crocs (NASDAQ: CROX) and a price target of $23. Benchmark comments, “We are initiating coverage on shares of Crocs with a Buy rating and 12-month price target of $23. Although timing is a concern given the lack of any near-term catalysts and seasonality,...

Benchmark maintains a Buy rating on True Religion Apparel (NASDAQ: TRLG) and a price target of $38. Benchmark notes, “We believe spring/summer fashion was well received with lots of color, and strong sell through, and as product is more competitively priced. We have also noticed a trend towards...

In a report published earlier, Benchmark reiterates a Buy rating on Kratos Defense & Security Solutions (NASDAQ: KTOS) and a price target of $8. Benchmark notes, “Management expects the CEI acquisition to close in early July. We estimate CEI will add $50+ million in sales and $6 million in FCF...

In a report published earlier, Benchmark reiterates Buy rating on Smith & Wesson (NASDAQ: SWHC) and a price target of $9. Benchmark notes, “Smith & Wesson is scheduled to report its Q4FY12 (April-end) on Thursday, June 28, after the close. The call is at 5PM EDT. In late May, SWHC pre-...

In a report published earlier today, Benchmark reiterated a Buy rating for The Pantry (NASDAQ: PTRY) and a price target of $20. Benchmark comments, “We are raising our 3Q12 EPS estimate by $0.14 to $0.59, from $0.45. If this environment continues through September, it could also produce upside to...

Benchmark reiterates a Buy rating for Nielsen Holdings (NYSE: NLSN) and a price target of $34. Benchmark notes, “Nielsen lowered its top-line revenue guidance from 5-7% to 5-6% y/y. As a result, we are trimming our revenues and EPS estimates to reflect a slight slowdown in Insight revenue growth...

In a report published earlier today, Benchmark remains at a Buy rating on Liquidity Services (NASDAQ: LQDT) and a price target of $73. Benchmark remarks, “Shares of Liquidity Services (LQDT-Buy, PT $73) have fallen 10% over the past month as investors likely cashed in on the stock's strong run....

Benchmark reiterates a Buy rating on ICU Medical (NASDAQ: ICUI) and a price target of $60. Benchmark comments, “ICU Medical and Mobius Therapeutics jointly announced that ICUI's ChemoClave system for the safe handling of hazardous drugs will be packaged with Mobius Therapeutics Mitosol kit. We...

Benchmark reiterates an Overweight rating for Susser Holdings Corp. (NASDAQ: SUSS) and increased the price target to $38. Benchmark comments, “We are raising our 2Q12 EPS estimate by $0.12, to $0.76 from $0.64. We also believe that miles driven could be increasing, benefiting comps. If this...